News for NeuroBo Pharmaceuticals, Inc. (NRBO)

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a strategic move by acquiring an additional 27,401 shares of MetaVia Inc (MTVA) at a price

MetaVia reports positive DA-1241 trial results for MASH

MTVA stock touches 52-week low at $2.04 amid market challenges

PR NewswireCAMBRIDGE, Mass., Nov. 18, 2024 New Nasdaq Ticker Symbol will be MTVACAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, In

Oklo, NuScale surge as Google backs new small nuclear reactors to power AI. Frontier's second-largest holder plans to vote against sale to Verizon - Reuters.

NRBO stock touches 52-week low at $2.55 amid market challenges

NeuroBo partners for long-acting obesity treatment

NeuroBo Pharmaceuticals announces exclusive license agreement with MThera Pharma for NB-01 to treat diabetic neuropathy, paving way for potential Phase 3...

Loading... Loading... The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or...

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 196 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

NeuroBo secures $20 million in private placement

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

NeuroBo Pharmaceuticals, Inc. May 2024 NASDAQ: NRBO ...

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 38,204.88 while the NASDAQ rose 0.77% to 15,281.03. The S&P 500 also rose, gaining, 0.49% to 4,869.54.

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

The increasing prevalence of diabetes patients, rise in screening for pain among diabetics, increase in the geriatric population, and launch of newly...

Gainers